LeMaitre Vascular (LMAT) Competitors

LeMaitre Vascular (NASDAQ:LMAT) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.

Does the media prefer LMAT or NVCR?

In the previous week, LeMaitre Vascular had 3 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for LeMaitre Vascular and 0 mentions for NovoCure. NovoCure's average media sentiment score of 0.40 beat LeMaitre Vascular's score of 0.09 indicating that NovoCure is being referred to more favorably in the news media.

Company	Overall Sentiment
LeMaitre Vascular	Neutral
NovoCure	Neutral

Is LMAT or NVCR more profitable?

LeMaitre Vascular has a net margin of 15.56% compared to NovoCure's net margin of -40.65%. LeMaitre Vascular's return on equity of 10.57% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	15.56%	10.57%	9.15%
NovoCure	-40.65%	-51.63%	-17.90%

Which has stronger valuation & earnings, LMAT or NVCR?

LeMaitre Vascular has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$193.48M	7.22	$30.10M	$1.34	46.73
NovoCure	$509.34M	2.55	-$207.04M	-$1.95	-6.18

Do institutionals and insiders believe in LMAT or NVCR?

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 12.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 5.7% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor LMAT or NVCR?

LeMaitre Vascular received 30 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 70.80% of users gave LeMaitre Vascular an outperform vote while only 63.89% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
LeMaitre Vascular	Outperform Votes 497 70.80%	Underperform Votes 205 29.20%
NovoCure	Outperform Votes 467 63.89%	Underperform Votes 264 36.11%

Do analysts recommend LMAT or NVCR?

LeMaitre Vascular currently has a consensus price target of $68.20, suggesting a potential upside of 8.91%. NovoCure has a consensus price target of $31.13, suggesting a potential upside of 158.30%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
NovoCure	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

Which has more volatility and risk, LMAT or NVCR?

LeMaitre Vascular has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats NovoCure on 14 of the 18 factors compared between the two stocks.